- Home
- AVTX vs DOMH Comparison
AVTX vs DOMH Comparison
Compare AVTX & DOMH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- DOMH
- Stock Information
- Founded
- AVTX 2011
- DOMH 1967
- Country
- AVTX United States
- DOMH United States
- Employees
- AVTX N/A
- DOMH N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- DOMH Biotechnology: Pharmaceutical Preparations
- Sector
- AVTX Health Care
- DOMH Health Care
- Exchange
- AVTX Nasdaq
- DOMH Nasdaq
- Market Cap
- AVTX 90.9M
- DOMH 12.1M
- IPO Year
- AVTX 2015
- DOMH N/A
- Fundamental
- Price
- AVTX $8.91
- DOMH $1.26
- Analyst Decision
- AVTX Strong Buy
- DOMH
- Analyst Count
- AVTX 4
- DOMH 0
- Target Price
- AVTX $33.00
- DOMH N/A
- AVG Volume (30 Days)
- AVTX 139.6K
- DOMH 12.6K
- Earning Date
- AVTX 11-07-2024
- DOMH 11-08-2024
- Dividend Yield
- AVTX N/A
- DOMH N/A
- EPS Growth
- AVTX N/A
- DOMH N/A
- EPS
- AVTX N/A
- DOMH N/A
- Revenue
- AVTX $820,000.00
- DOMH $12,589,000.00
- Revenue This Year
- AVTX N/A
- DOMH N/A
- Revenue Next Year
- AVTX N/A
- DOMH N/A
- P/E Ratio
- AVTX N/A
- DOMH N/A
- Revenue Growth
- AVTX N/A
- DOMH 1117.50
- 52 Week Low
- AVTX $3.95
- DOMH $1.24
- 52 Week High
- AVTX $34.46
- DOMH $3.20
- Technical
- Relative Strength Index (RSI)
- AVTX 34.34
- DOMH 25.29
- Support Level
- AVTX $9.00
- DOMH $1.66
- Resistance Level
- AVTX $9.99
- DOMH $1.72
- Average True Range (ATR)
- AVTX 0.84
- DOMH 0.09
- MACD
- AVTX -0.02
- DOMH -0.04
- Stochastic Oscillator
- AVTX 5.79
- DOMH 3.70
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About DOMH Dominari Holdings Inc.
Dominari Holdings Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company's oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia.